Will This Obesity Biotech's Latest Scheme Boost Sales?

Drugmaker VIVUS (NASDAQ: VVUS  ) has struggled to ramp up sales of its recently approved obesity medication Qsymia. With competition from Arena Pharmaceuticals  (NASDAQ: ARNA  ) and its partner Eisai (NASDAQOTH: ESALY  ) looming once their drug Belviq clears DEA scheduling, VIVUS has launched the Save Now! program. In this video, health care analyst Max Macaluso discusses how this new program will impact VIVUS' business and how it might affect the competitive landscape of the obesity market.

Who will win the obesity drug market?
Can VIVUS pick up its lagging sales and fend off the competition, or will Arena Pharmaceuticals reign supreme in the obesity space? If you're in the dark, grab copies of The Motley Fool's premium research reports on VIVUS and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and VIVUS -- complete with a full year of free updates -- today.

Editor's note: This video was filmed on March 5, 2013.


Read/Post Comments (5) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 06, 2013, at 10:33 AM, krapbuster wrote:

    No- this scheme is VVUS's deathbed for Qsymia as virtually nobody is buying. Drug is reformulated generic combo on market many years while USA obesity rates tripled.

    Everyone waiting for Belviq's launch which will become the worldwide blockbuster.

  • Report this Comment On March 06, 2013, at 12:52 PM, gazoo99 wrote:

    Well RSRdriver......

    That's not hard to figure out since you have your facts all wrong as usual.

    Pricing Qsymia where they did is like one of those BAD DISCOUNT FURNITURE STORES, blowing out the cheap furniture, you know those guys on TV??.

    OOPS..... I forgot..... VVUS can't do that!

    No advertizing on TV!!!!

    GEE NOW WHAT????

    If at first you don't succeed try....try....again.

    It won't sell at a regular pricing where shareholders & the company can actually make money.......so.....

    I know.......lets discount it....... to give it away.......blow it out the door.......

    I don't know about you but.......

    I'd sooner have a good quality Rib-Eye steak

    over a Micky D's burger any day if ya know what I mean.

    That's as good as a comparison for Belqiv (Rib-Eye) and Qsymia (Micky D's) that I can think of at the moment.

  • Report this Comment On March 06, 2013, at 1:11 PM, PhillyDan wrote:

    Actually RSRdriver, have you ever seen head to head study results of Q vs. B? Well until you do, you cannot make a comparison based on two totally different separate studies.

    In addition, 35% of the people that completed the drug arm for Belviq or 35% of 1800 people - which btw is more people than were in the Q studies - lost 10% or greater; 25% lost 16.7% or greater. Thus your comment is wrong when you look at the actual completer data. But just as important as the weight loss is the safety profile of a drug and Belviq's safety profile is better and the drug is more tolerable than Q.

    Not that I believe it is needed but a number of Doctor's will add a dosage of phentermine scrip along with the Belviq scrip for certain patients. That weight loss could probably exceed any weight loss seen by Q.

    The reality is that financially Vivus has problems, they are burning money and will burn more money with this program. Now as said in the video, if the program works, it could pay off down the line.

    But, very soon, Vivus is going to have to start shelling out money for the CVOT and nine other studies. The CVOT study will be costly and will stretch/stress the financial's for Vivus. There is no partner and to make matters worse Avanafil sits on the sideline while Vivus is attempting to get a partner to commercialize Avanafil. Maybe it will happen if Avanafil does receive EU approval, which is likely. But if a partnership does not happen, Vivus is going to have to raise some serious capital. Not bashing, these are the hard cold facts.

  • Report this Comment On March 06, 2013, at 2:58 PM, Retaility wrote:

    Up 7%.... Drink that kool-aid

  • Report this Comment On March 06, 2013, at 4:47 PM, RSRdriver wrote:

    In case you are wondering why my TRUTHFUL comments on Belviq vanished. It's an Areniac tactic. If they cannot respond to facts, they try and make them go away.

    I can't wait till the PPS drops to $4 and they go away!

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2296438, ~/Articles/ArticleHandler.aspx, 8/20/2014 7:14:41 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement